Management  of  asthma and copd









A chronic inflammatory disorder of the
airway
Infiltration of mast cells, eosinophils
and lymphocytes
Airway hyperresponsiveness
Recurrent episodes of wheezing,
coughing and shortness of breath
Widespread, variable and often
reversible airflow limitation
Management  of  asthma and copd
Predisposing Factors


Atopy

Causal Factors


Indoor Allergens







Outdoor Allergens





Domestic mites
Animal Allergens
Cockroach Allergens
Fungi
Pollens
Fungi

Occupational Sensitizers

Contributing Factors

Respiratory infections
Small size at birth
 Diet
 Air pollution



– Outdoor pollutants
– Indoor pollutants



Smoking

– Passive Smoking
– Active Smoking
Environmental
factors

Mucosal inflammation
Atopic
sensitization
Phenotype

Genetic factors
Structural changes
1.

Extrinsic or allergic:







1.

History of `atopy` in childhood
Family history of allergies
Positive skin test
Raised IgE level
Below 30 years of age
Less prone to status asthmaticus

Intrinsic or Idiosyncratic:






No family history of allergy
Negative skin test
No rise in IgE level
Middle age onset
Prone to status asthmaticus
CLASSIFY SEVERITY

STEP 4
Severe
Persistent
STEP 3
Moderate
Persistent
STEP 2
Mild
Persistent
STEP 1
Intermittent

Clinical Features Before Treatment
Nighttime
PEF
Symptoms
Symptoms
Continuous
<60% predicted
Limited physical Frequent
Variability >30%
activity
Daily
Use β2-agonist
daily
Attacks affect
activity a week
>1 time

but <1 time a
day
< 1 time a week
Asymptomatic
and normal PEF
between attacks

>1 time week

>2 times a month

<2 times a month

>60%-<80%
predicted
Variability >30%
>80% predicted
Variability 2030%
>80% predicted
Variability <20%

The presence of one of the features of severity is sufficient to place a patient in that
category.
Global Initiative for Asthma (GINA) WHO/NHLBI, 2002


GINA Guideline clearly states that THERE
IS NO CURE FOR ASTHMA, But
appropriate management most often
leading to CONTROL of asthma





Relievers
Preventers
Peak Flow meter
Patient education
-

Rescue medications
Quick relief of symptoms
Used during acute attacks
Action lasts 4-6 hrs








Short acting β 2 agonists
Salbutamol
Levosalbutamol
Anti-cholinergics
Ipratropium bromide
Xanthines
Theophylline
Adrenaline injections
Selective β2 agonist

ATP
cAMP

Relaxation
Theophyline

5’-AMP

Ipratopium
Ach

Vagus nerve
-

Prevent future attacks
Long term control of asthma
Prevent airway remodelling
Corticosteroids
Prednisolone, Betamethasone
Beclomethasone, Budesonide
Fluticasone
Long acting β2 agonists
Bambuterol, Salmeterol
Formoterol

Anti-leukotrienes
Montelukast, Zafirlukast
Xanthines
Theophylline SR
Mast cell stabilisers
Sodium cromoglycate

COMBINATIONS
Salmeterol/Fluticasone
Formoterol/Budesonide
Salbutamol/Beclomethasone
SALBUTAMOL INHALER
100 mcg:
1 or 2 puffs as necessary
LEVOSALBUTAMOL INHALER
50 mcg :
1 or 2 puffs as necessary


Formoterol ( fast relief and sustained
relief ) +



Budesonide ( twice or even once
daily use )
Dose: 1- 4 puffs ( OD/BD )

Another combination
Salmeterol + Fluticasone


Metered dose inhalers



Dry powder inhalers

(Rotahaler)


Spacers / Holding chambers
Dry Powder
Inhaler

Metered Dose inhaler

Spacer
Management  of  asthma and copd








Step I: When symptoms are less than once daily occasional inhalation of a short acting Beta-2 agonist –
salbutmol, terbutaline. If used more than once daily –
step II (Mild episodic asthma)
Step II: Regular inhalation of low-dose steroids.
Alternatively, cromoglycates. Beta-2 agonist as and
whenever required (Mild chronic asthma)
Step III: Inhalation of high dose of steroids (800 mcg) +
Beta-2 agonist. Sustained release theophylline may be
added. LT inhibitors may be tried instead of steroids
(Moderate asthma with frequent exacerbations) spacers
Step IV: Higher dose of steroid (800 to 200 mcg) +
regular beta-2 agonist (long acting salmeterol)
Additional treatment with oral drugs – LT antagonist
or SR theophylline or oral beat-2 agonist
Management  of  asthma and copd
allergen
allergen
avoidance
avoidance

indicated
indicated
when possible
when possible

pharmacotherapy
pharmacotherapy
safety
safety
effectiveness
effectiveness
easy to be administered
easy to be administered

AR
AR

patient's
patient's
education
education

immunotherapy
immunotherapy

always indicated
always indicated

effectiveness
effectiveness
specialist prescription
specialist prescription
may alter the natural
may alter the natural
course of the disease
course of the disease
Birth:TH2
Older siblings:
Many infections
[TH1 stimuli]

Allergen
Exposure

TH1
No allergies

Source: Busse WW, Lemanske RF. N Engl J Med 2001.

Only child:
Few infections

Still TH2
Allergies







Patients diagnosed with
allergic asthma
Patients diagnosed with
allergies such as hay
fever
Patients diagnosed with
sinusitis that predisposes
them to asthma
Patients diagnosed with
insect sting allergy


COPD is characterized by airflow limitation caused by
chronic bronchitis or emphysema often associated with
long term tobacco smoking



This is usually a slowly progressive and largely
irreversible process



Consists of increased resistance to airflow, loss of
elastic recoil, decreased expiratory flow rate, and
overinflation of the lung.



COPD is clinically defined by a low FEV1 value that
fails to respond acutely to bronchodilators, a
characteristic that differentiates it from asthma.


Chronic Bronchitis is characterized by
Chronic inflammation and excess mucus production
 Presence of chronic productive cough




Emphysema is characterized by
Damage to the small, sac-like units of the lung that
deliver oxygen into the lung and remove the carbon
dioxide
 Chronic cough


*Source: Braman, S. Update on the ATS Guidelines for COPD. Medscape Pulmonary Medicine. 2005;9(1):1.
Management  of  asthma and copd
Normal versus Diseased Bronchi




Smoking
Air pollution
genetic (hereditary) risk


Night time waking with breathlessness or
wheeze is common in asthma and uncommon in
COPD.



COPD is rare before the age of 35 whilst asthma
is common in under-35.
Classification of COPD Severity
by Spirometry
Stage I: Mild

FEV1/FVC < 0.70
FEV1 > 80% predicted

Stage II: Moderate

FEV1/FVC < 0.70
50% < FEV1 < 80% predicted

Stage III: Severe

FEV1/FVC < 0.70
30% < FEV1 < 50% predicted

Stage IV: Very Severe

FEV1/FVC < 0.70
FEV1 < 30% predicted or
FEV1 < 50% predicted plus
Physical examination
Signs of heavy smokers

Observe for clubbing

Distended neck vein on expiration

The presence of barrel chest

Observe for abdominal breathing

The use of pursed lips breathing and chest
movement

Auscultate the chest& listen for musical wheezes
characteristics of chronic bronchitis

Management  of  asthma and copd









Symptoms
Physical examination
Sample of sputum
Chest x-ray
High-resolution CT (HRCT scan)
Pulmonary function test (spirometery)
Arterial blood gases test
Pulse oximeter


Give antibiotics to treat infection



Give bronchodilators to relieve bronchospasm, reduce
airway obstruction, mucosal edema and liquefy
secretions.



Chest physiotherapy and postural drainage to improve
pulmonary ventilation.



Proper hydration helps to cough up secretions or
tracheal suctioning when the patient is unable to cough.



Steroid therapy if the patient fails to respond to more
conservative treatment.


Stop smoking



Oxygenation with low concentration during the acute episodes



In asthma adrenaline ( epinephrine) SC if the bronchospasm not
relieved.



Aminophylins IV if the above treatment does not help.



IV corticosteroids for patients with chronic asthma or frequent attack.



Sedative or tranquilizers to calm the patient.



Increase fluids intake to correct loss of diaphoresis and inaccessible
loss of hyperventilation.



Intubations and mechanical ventilation if there is respiratory failure .
Oxygen therapy




Used as long-term continuous therapy, during exercise,
or to relieve acute dyspnea
Improves survival in COPD patients with severe
hypoxemia (partial pressure of oxygen [pO2] < 55 mm
Hg or oxygen saturation [sO2] <88%) (Strength of
Recommendation [SOR]: A)




When used for >15 hours daily

Does not improve survival in patients with moderate
Cranston, 2008
hypoxemia or desaturation at night
GOLD, 2009


Annual flu vaccine




Reduces risk of flu and its complications

Pneumonia vaccine


Reduces risk of common cause of pneumonia
G lobal Initiative for Chronic
bstructive
O ung
L isease

D

November 19, 2006
World COPD Day, Kyoto Japan
Revised 2006

Definition, Classification
Burden of COPD
Risk factors
Pathogenesis, pathology,
pathophysiology
Management
Practical Considerations
THANK YOU

More Related Content

PPTX
Childhood asthma
PPTX
Acute severe asthma
PPTX
Asthma ppt
PPTX
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
PPT
History taking
PPTX
PPTX
Upper airway obstruction
Childhood asthma
Acute severe asthma
Asthma ppt
Chronic Obstructive Pulmonary Disease (COPD) by Dr Kemi Dele
History taking
Upper airway obstruction

What's hot (20)

PPTX
Bronchiectasis
PPTX
Bronchial asthama
PPT
ASTHMA
PPTX
interstitial lung diseases
PPT
19.bronchial asthma
PPTX
PPTX
CASE PRESENTATION ON ARF
PPTX
Management of Hemothorax -Slide.pptx
PPTX
Asthma-COPD Overlap Syndrome(ACOS)- an update
PPTX
Acute severe asthma management 2020
PDF
Asthma Review - GINA guidelines summary 2024
PPTX
PPTX
Asthma and COPD exacerbation - Emergency
PPT
Indications and Modes of Mechanical Ventilation
PPT
Copd lecture notes
PPTX
Copd ppt (1)
PPT
Asthma
PPT
Lecture 5 asthma and copd
PPT
Bronchiectasis
Bronchial asthama
ASTHMA
interstitial lung diseases
19.bronchial asthma
CASE PRESENTATION ON ARF
Management of Hemothorax -Slide.pptx
Asthma-COPD Overlap Syndrome(ACOS)- an update
Acute severe asthma management 2020
Asthma Review - GINA guidelines summary 2024
Asthma and COPD exacerbation - Emergency
Indications and Modes of Mechanical Ventilation
Copd lecture notes
Copd ppt (1)
Asthma
Lecture 5 asthma and copd
Ad

Viewers also liked (14)

PPTX
Asthma vs COPD - A quick summary of the differences between them
PDF
Is COPD an inflammatory disease?
PPT
Asthma copd
PPTX
Copd and asthma
PPT
Asthma and COPD
PPTX
Asthma and COPD
PPT
Bronchial Asthma
PPTX
Asthma-COPD Overlap Syndrome (ACOS)
PPTX
Perioperative management of asthma and COPD
PPT
3 Asthma and COPD Management
PPT
Management Of Copd & Asthma
PPTX
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PPT
Free radicals
PPTX
Chronic obstructive pulmonary disease (copd) power point
Asthma vs COPD - A quick summary of the differences between them
Is COPD an inflammatory disease?
Asthma copd
Copd and asthma
Asthma and COPD
Asthma and COPD
Bronchial Asthma
Asthma-COPD Overlap Syndrome (ACOS)
Perioperative management of asthma and COPD
3 Asthma and COPD Management
Management Of Copd & Asthma
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Free radicals
Chronic obstructive pulmonary disease (copd) power point
Ad

Similar to Management of asthma and copd (20)

PPT
Chronic obstructive pulmonary disease ppt
PPT
Obstructive lung disease
PPTX
Conditions of the lower respiratory tract.pptx
PDF
ASTHMA, is a conition of lower respiratory tract
PPTX
Obstructive Lung Disease
PPTX
ASTHMA.pptx
PPT
Presentation on Treatment of Bronchial Asthma | Jindal Chest Clinic
PPTX
bronchialasthma-160310160551.pptx
PPT
Asthma and COPD med.ppt
PPT
Pulmonary Diseases 2009 copy
PPT
Pulmonary Diseases
PPT
Bronchial Asthma and COPD | Jindal Chest Clinic
PDF
Dental management of patient with Pulmonary diseases
PPTX
Copd
PPTX
Bronchial asthma
PPTX
Pulmonology.pptx
PPTX
Respiratory disorders.pptx
PPTX
7 Asthma & COAD What a Primary Physician need to know.pptx
PPT
INTEGRATED THERAPEUTICS I.ppt
Chronic obstructive pulmonary disease ppt
Obstructive lung disease
Conditions of the lower respiratory tract.pptx
ASTHMA, is a conition of lower respiratory tract
Obstructive Lung Disease
ASTHMA.pptx
Presentation on Treatment of Bronchial Asthma | Jindal Chest Clinic
bronchialasthma-160310160551.pptx
Asthma and COPD med.ppt
Pulmonary Diseases 2009 copy
Pulmonary Diseases
Bronchial Asthma and COPD | Jindal Chest Clinic
Dental management of patient with Pulmonary diseases
Copd
Bronchial asthma
Pulmonology.pptx
Respiratory disorders.pptx
7 Asthma & COAD What a Primary Physician need to know.pptx
INTEGRATED THERAPEUTICS I.ppt

Recently uploaded (20)

PDF
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
PPTX
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
PDF
OSCE Series ( Questions & Answers ) - Set 6.pdf
DOCX
PEADIATRICS NOTES.docx lecture notes for medical students
PPTX
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
PPT
Infections Member of Royal College of Physicians.ppt
PPTX
Neonate anatomy and physiology presentation
PPTX
09. Diabetes in Pregnancy/ gestational.pptx
PPTX
Acute Coronary Syndrome for Cardiology Conference
PPTX
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
PPTX
y4d nutrition and diet in pregnancy and postpartum
PDF
Transcultural that can help you someday.
PPT
neurology Member of Royal College of Physicians (MRCP).ppt
PDF
Copy of OB - Exam #2 Study Guide. pdf
PDF
AGE(Acute Gastroenteritis)pdf. Specific.
PDF
Calcified coronary lesions management tips and tricks
PPTX
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
PDF
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
PPTX
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
PDF
OSCE Series Set 1 ( Questions & Answers ).pdf
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
OSCE Series ( Questions & Answers ) - Set 6.pdf
PEADIATRICS NOTES.docx lecture notes for medical students
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
Infections Member of Royal College of Physicians.ppt
Neonate anatomy and physiology presentation
09. Diabetes in Pregnancy/ gestational.pptx
Acute Coronary Syndrome for Cardiology Conference
IMAGING EQUIPMENiiiiìiiiiiTpptxeiuueueur
y4d nutrition and diet in pregnancy and postpartum
Transcultural that can help you someday.
neurology Member of Royal College of Physicians (MRCP).ppt
Copy of OB - Exam #2 Study Guide. pdf
AGE(Acute Gastroenteritis)pdf. Specific.
Calcified coronary lesions management tips and tricks
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
04 dr. Rahajeng - dr.rahajeng-KOGI XIX 2025-ed1.pdf
CARDIOVASCULAR AND RENAL DRUGS.pptx for health study
OSCE Series Set 1 ( Questions & Answers ).pdf

Management of asthma and copd

  • 2.      A chronic inflammatory disorder of the airway Infiltration of mast cells, eosinophils and lymphocytes Airway hyperresponsiveness Recurrent episodes of wheezing, coughing and shortness of breath Widespread, variable and often reversible airflow limitation
  • 4. Predisposing Factors  Atopy Causal Factors  Indoor Allergens      Outdoor Allergens    Domestic mites Animal Allergens Cockroach Allergens Fungi Pollens Fungi Occupational Sensitizers Contributing Factors Respiratory infections Small size at birth  Diet  Air pollution   – Outdoor pollutants – Indoor pollutants  Smoking – Passive Smoking – Active Smoking
  • 6. 1. Extrinsic or allergic:       1. History of `atopy` in childhood Family history of allergies Positive skin test Raised IgE level Below 30 years of age Less prone to status asthmaticus Intrinsic or Idiosyncratic:      No family history of allergy Negative skin test No rise in IgE level Middle age onset Prone to status asthmaticus
  • 7. CLASSIFY SEVERITY STEP 4 Severe Persistent STEP 3 Moderate Persistent STEP 2 Mild Persistent STEP 1 Intermittent Clinical Features Before Treatment Nighttime PEF Symptoms Symptoms Continuous <60% predicted Limited physical Frequent Variability >30% activity Daily Use β2-agonist daily Attacks affect activity a week >1 time but <1 time a day < 1 time a week Asymptomatic and normal PEF between attacks >1 time week >2 times a month <2 times a month >60%-<80% predicted Variability >30% >80% predicted Variability 2030% >80% predicted Variability <20% The presence of one of the features of severity is sufficient to place a patient in that category. Global Initiative for Asthma (GINA) WHO/NHLBI, 2002
  • 8.  GINA Guideline clearly states that THERE IS NO CURE FOR ASTHMA, But appropriate management most often leading to CONTROL of asthma
  • 10. - Rescue medications Quick relief of symptoms Used during acute attacks Action lasts 4-6 hrs
  • 11.     Short acting β 2 agonists Salbutamol Levosalbutamol Anti-cholinergics Ipratropium bromide Xanthines Theophylline Adrenaline injections
  • 13. - Prevent future attacks Long term control of asthma Prevent airway remodelling
  • 14. Corticosteroids Prednisolone, Betamethasone Beclomethasone, Budesonide Fluticasone Long acting β2 agonists Bambuterol, Salmeterol Formoterol Anti-leukotrienes Montelukast, Zafirlukast Xanthines Theophylline SR Mast cell stabilisers Sodium cromoglycate COMBINATIONS Salmeterol/Fluticasone Formoterol/Budesonide Salbutamol/Beclomethasone
  • 15. SALBUTAMOL INHALER 100 mcg: 1 or 2 puffs as necessary LEVOSALBUTAMOL INHALER 50 mcg : 1 or 2 puffs as necessary
  • 16.  Formoterol ( fast relief and sustained relief ) +  Budesonide ( twice or even once daily use ) Dose: 1- 4 puffs ( OD/BD ) Another combination Salmeterol + Fluticasone
  • 17.  Metered dose inhalers  Dry powder inhalers (Rotahaler)  Spacers / Holding chambers
  • 20.     Step I: When symptoms are less than once daily occasional inhalation of a short acting Beta-2 agonist – salbutmol, terbutaline. If used more than once daily – step II (Mild episodic asthma) Step II: Regular inhalation of low-dose steroids. Alternatively, cromoglycates. Beta-2 agonist as and whenever required (Mild chronic asthma) Step III: Inhalation of high dose of steroids (800 mcg) + Beta-2 agonist. Sustained release theophylline may be added. LT inhibitors may be tried instead of steroids (Moderate asthma with frequent exacerbations) spacers Step IV: Higher dose of steroid (800 to 200 mcg) + regular beta-2 agonist (long acting salmeterol) Additional treatment with oral drugs – LT antagonist or SR theophylline or oral beat-2 agonist
  • 22. allergen allergen avoidance avoidance indicated indicated when possible when possible pharmacotherapy pharmacotherapy safety safety effectiveness effectiveness easy to be administered easy to be administered AR AR patient's patient's education education immunotherapy immunotherapy always indicated always indicated effectiveness effectiveness specialist prescription specialist prescription may alter the natural may alter the natural course of the disease course of the disease
  • 23. Birth:TH2 Older siblings: Many infections [TH1 stimuli] Allergen Exposure TH1 No allergies Source: Busse WW, Lemanske RF. N Engl J Med 2001. Only child: Few infections Still TH2 Allergies
  • 24.     Patients diagnosed with allergic asthma Patients diagnosed with allergies such as hay fever Patients diagnosed with sinusitis that predisposes them to asthma Patients diagnosed with insect sting allergy
  • 25.  COPD is characterized by airflow limitation caused by chronic bronchitis or emphysema often associated with long term tobacco smoking  This is usually a slowly progressive and largely irreversible process  Consists of increased resistance to airflow, loss of elastic recoil, decreased expiratory flow rate, and overinflation of the lung.  COPD is clinically defined by a low FEV1 value that fails to respond acutely to bronchodilators, a characteristic that differentiates it from asthma.
  • 26.  Chronic Bronchitis is characterized by Chronic inflammation and excess mucus production  Presence of chronic productive cough   Emphysema is characterized by Damage to the small, sac-like units of the lung that deliver oxygen into the lung and remove the carbon dioxide  Chronic cough  *Source: Braman, S. Update on the ATS Guidelines for COPD. Medscape Pulmonary Medicine. 2005;9(1):1.
  • 30.  Night time waking with breathlessness or wheeze is common in asthma and uncommon in COPD.  COPD is rare before the age of 35 whilst asthma is common in under-35.
  • 31. Classification of COPD Severity by Spirometry Stage I: Mild FEV1/FVC < 0.70 FEV1 > 80% predicted Stage II: Moderate FEV1/FVC < 0.70 50% < FEV1 < 80% predicted Stage III: Severe FEV1/FVC < 0.70 30% < FEV1 < 50% predicted Stage IV: Very Severe FEV1/FVC < 0.70 FEV1 < 30% predicted or FEV1 < 50% predicted plus
  • 32. Physical examination Signs of heavy smokers  Observe for clubbing  Distended neck vein on expiration  The presence of barrel chest  Observe for abdominal breathing  The use of pursed lips breathing and chest movement  Auscultate the chest& listen for musical wheezes characteristics of chronic bronchitis 
  • 34.         Symptoms Physical examination Sample of sputum Chest x-ray High-resolution CT (HRCT scan) Pulmonary function test (spirometery) Arterial blood gases test Pulse oximeter
  • 35.  Give antibiotics to treat infection  Give bronchodilators to relieve bronchospasm, reduce airway obstruction, mucosal edema and liquefy secretions.  Chest physiotherapy and postural drainage to improve pulmonary ventilation.  Proper hydration helps to cough up secretions or tracheal suctioning when the patient is unable to cough.  Steroid therapy if the patient fails to respond to more conservative treatment.
  • 36.  Stop smoking  Oxygenation with low concentration during the acute episodes  In asthma adrenaline ( epinephrine) SC if the bronchospasm not relieved.  Aminophylins IV if the above treatment does not help.  IV corticosteroids for patients with chronic asthma or frequent attack.  Sedative or tranquilizers to calm the patient.  Increase fluids intake to correct loss of diaphoresis and inaccessible loss of hyperventilation.  Intubations and mechanical ventilation if there is respiratory failure .
  • 37. Oxygen therapy   Used as long-term continuous therapy, during exercise, or to relieve acute dyspnea Improves survival in COPD patients with severe hypoxemia (partial pressure of oxygen [pO2] < 55 mm Hg or oxygen saturation [sO2] <88%) (Strength of Recommendation [SOR]: A)   When used for >15 hours daily Does not improve survival in patients with moderate Cranston, 2008 hypoxemia or desaturation at night GOLD, 2009
  • 38.  Annual flu vaccine   Reduces risk of flu and its complications Pneumonia vaccine  Reduces risk of common cause of pneumonia
  • 39. G lobal Initiative for Chronic bstructive O ung L isease D November 19, 2006 World COPD Day, Kyoto Japan
  • 40. Revised 2006 Definition, Classification Burden of COPD Risk factors Pathogenesis, pathology, pathophysiology Management Practical Considerations

Editor's Notes

  • #6: Environmental and genetic factors lead to atopic sensitization, which may be asymptomatic. Together with local tissue factors it can develop to clinical disease. The balance between these factors is responsible for the allergic phenotype
  • #7: Atopy involves the capacity to produce IgE in response to common environmental proteins such as house dustmite, grass pollen, and food allergens. From the Greek atopos meaning out of place. A hereditary disorder marked by the tendency to develop immediate allergic reactions to substances such as pollen, food, dander, and insect venoms and manifested by hay fever, asthma, or similar allergic conditions. Also called atopic allergy. Atopy involves the capacity to produce IgE in response to common environmental proteins such as house dustmite, grass pollen, and food allergens. From the Greek atopos meaning out of place.
  • #17: This combination is available today in both metered dose and dry powder inhalers (Rotacaps). It is available in 3 different Rotacap strengths where the dose of formoterol remains constant but the budesonide dose varies according to the need (severity of asthma); i.e. 100, 200 and 400 mcg of budesonide in 3 different Rotacaps.
  • #24: One theory that might explain why we seem to be more vulnerable than ever to allergic disease is called the hygiene hypothesis. We’re all born with an abundance of TH2 immune cells designed to fight internal parasites. Exposure to infections triggers the development of TH1 immune cells, designed to fight bacteria and viruses, shown here on the left. Press space bar With no exposure to infections, the TH1 immune cells never take over, illustrated by the right arrow. Investigators theorize that with few parasites to conquer in the modernized West, TH2 immune cells might have turned on harmless allergens instead, resulting in more allergic disease. This hypothesis is based on studies showing lower asthma rates for children who live on farms, attend day care centers, have indoor pets or older siblings; all things that expose children to higher levels of bacteria and infection. Children who have delayed development of TH1 cells, possibly because they aren’t exposed to infections through contact with animals, dirt and other children, seem to have more allergies and might be more predisposed to asthma. Press space bar SOURCE: Busse WW, Lemanske RF. Advances in Immunology. NEJM. 2001 Feb; 344(5):350-362.
  • #25: So who can be helped by this treatment? Patients diagnosed with allergic asthma. Patients with allergies such as hay fever. Patients diagnosed with sinusitis that predisposes them to asthma. Patients diagnosed with an allergy to insect stings. Press space bar
  • #38: When used for more than 15 hours per day in patients with severe COPD (pO2 &lt; 60 mm Hg), oxygen has been shown to increase survival. It doesn’t improve survival in patients with only moderate COPD or nocturnal desaturation only. Benefits on quality of life are unclear, but oxygen may improve general alertness and psychological state in some patients. Oxygen therapy can be used as long-term with continuous delivery, only during exercise, or to relieve acute dyspnea. GOLD, 2009; Rabe, 2007; Cranston, 2008